or Try an Advanced Search...

    Technical Analysis for LABP - Landos Biopharma, Inc.

    Grade Last Price % Change Price Change
    A 22.15 0.87% 0.19
    LABP closed up 0.87 percent on Tuesday, April 23, 2024, on 31 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: May 10
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Extremely Strong Up Up Up
    Historical LABP trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing High Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    New 52 Week High Strength 0.00%
    BB Squeeze + Upper Band Touch Range Contraction 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Up 5 Days in a Row Strength 0.00%
    Older End-of-Day Signals for LABP ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 3 hours ago
    New 52 Week High about 3 hours ago
    Possible Inside Day about 5 hours ago
    60 Minute Opening Range Breakout about 6 hours ago
    60 Minute Opening Range Breakdown about 8 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    LABP Chart by TradingView
    Basic chart:

    Profile

    Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Diabetic Nephropathy

    Is LABP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 28 Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
    Mar 26 AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
    Mar 25 Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
    Mar 25 Landos shares rocket 170% on AbbVie takeover deal
    Mar 25 AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
    Mar 25 AbbVie to buy immune drug developer Landos
    Mar 21 Landos Biopharma reports Q4 results
    Mar 21 Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
    Mar 5 Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
    Jan 8 Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation
    See more LABP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.151
    52 Week Low 2.5
    Average Volume 29,651
    200-Day Moving Average 6.24
    50-Day Moving Average 12.73
    20-Day Moving Average 21.61
    10-Day Moving Average 21.70
    Average True Range 0.51
    RSI (14) 94.23
    ADX 77.18
    +DI 59.71
    -DI 2.73
    Chandelier Exit (Long, 3 ATRs) 20.62
    Chandelier Exit (Short, 3 ATRs) 9.23
    Upper Bollinger Bands 21.97
    Lower Bollinger Band 21.25
    Percent B (%b) 1.25
    BandWidth 3.35
    MACD Line 2.66
    MACD Signal Line 3.13
    MACD Histogram -0.4739
    Fundamentals Value
    Market Cap 69.04 Million
    Num Shares 3.12 Million
    EPS -3.85
    Price-to-Earnings (P/E) Ratio -5.75
    Price-to-Sales 2.37
    Price-to-Book 0.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.53
    Resistance 3 (R3) 22.49 22.32 22.46
    Resistance 2 (R2) 22.32 22.22 22.34 22.44
    Resistance 1 (R1) 22.23 22.16 22.28 22.28 22.42
    Pivot Point 22.07 22.07 22.09 22.09 22.07
    Support 1 (S1) 21.98 21.97 22.03 22.02 21.88
    Support 2 (S2) 21.82 21.91 21.84 21.86
    Support 3 (S3) 21.73 21.82 21.84
    Support 4 (S4) 21.77